Knowledge Hub
Moore Than Arthritis Resource Library
Welcome to the Moore Than Arthritis Resource Library. We believe that trusted information should be easy to find and accessible to everyone. Our Resource Library brings together our policies, guidance, educational resources and community information in one place. As our organisation grows, this library will continue to expand with new resources to support individuals, families, businesses, healthcare organisations and community partners.
About Moore Than Arthritis
Educational Resources
Click any resource to view it full size, then download the PDF.
Educational Resources
Daily Life and Self-Management
Premium Factsheets
- Download factsheet (PDF)
Early Inflammatory Arthritis
Why timely diagnosis and treatment matter.
- Download factsheet (PDF)
Mental Health & Long-Term Conditions
Practical information for individuals, families and carers.
Evidence & Research
Peer-reviewed research
Women's and Men's Reported Experiences of Autoimmune Disease Diagnosis
New peer-reviewed research involving 6,607 people highlights differences in women's and men's reported experiences of autoimmune disease diagnosis. Explore the findings, understand their limitations and discover why listening to patients matters.
UK Health Policy Update
MHRA Strategy 2030: What It Means for Patients
The MHRA has published its Strategy 2030, setting out plans to strengthen patient involvement, improve medicine safety and support access to innovative treatments. This Moore Than Arthritis briefing explains what those commitments could mean for people living with arthritis and other long-term health conditions.
Patients should have a meaningful voice in how medicines are developed, evaluated and monitored.
MHRA Strategy 2030 includes commitments relating to:
- Greater patient and public involvement
- Women's health
- Medicine safety and pharmacovigilance
- Access to medicines
- Innovation and clinical research
MHRA Strategy 2030 sets out strategic commitments and future direction. It does not represent a new arthritis treatment recommendation, a change to an individual's prescription or approval of a specific new arthritis medicine.
UK Health Briefing / Women's Health
Pregnancy & Autoimmune Conditions: Why Joined-Up Healthcare Matters
A new specialist rheumatology briefing highlights important lessons from the 2026 MBRRACE-UK maternal health report for women living with lupus, connective tissue disease and other inflammatory rheumatic conditions. This Moore Than Arthritis briefing explains why pregnancy planning, medicines review, communication between specialist teams and coordinated care can matter before, during and after pregnancy.
Safe pregnancy care begins with listening, planning and coordinated support.
Based on the British Society for Rheumatology's specialist interpretation of the 2026 MBRRACE-UK maternal health findings, this briefing covers:
- Six maternal deaths during 2022–2024 were attributed to connective tissue disorders
- Four of those deaths involved complications of systemic lupus erythematosus (SLE)
- The findings reinforce the importance of appropriate pre-pregnancy counselling
- Complex cases may require coordinated care between rheumatology, maternity and other specialist teams
- Medication and treatment planning can be particularly important before, during and after pregnancy
Important context: The national MBRRACE-UK report recorded 252 maternal deaths from direct and indirect causes during pregnancy or within 42 days after pregnancy in 2022–2024. This is the overall national figure and must not be interpreted as deaths caused by rheumatic disease.
Medicines safety: Do not stop, start or change prescribed arthritis or autoimmune medication because of this briefing. People who are pregnant, planning pregnancy or have questions about their treatment should discuss their individual circumstances with their rheumatology, maternity, GP or other appropriate specialist team.
Primary sources
UK Health Briefing / Accessibility & Rights
Accessible Air Travel: New UK Developments for Disabled Passengers
The UK Government has reported further progress towards making air travel more accessible for disabled and less-mobile passengers. This Moore Than Arthritis briefing explains developments around disability-awareness training, passenger assistance, accessibility information, pre-travel communication and mobility equipment — and clearly separates improvements being introduced from future protections that are still proposed.
The resource also provides practical considerations for people living with arthritis, chronic pain, fatigue, reduced mobility and fluctuating conditions when planning air travel.
This briefing covers:
- Better disability-awareness training for aviation staff
- Continued improvements to passenger assistance
- Clearer accessibility information for disabled passengers
- Development and trialling of digital pre-travel support approaches
- Proposed stronger protections relating to damaged wheelchairs and mobility aids
Important: Proposed Civil Aviation Bill measures concerning stronger enforcement and compensation limits for damaged wheelchairs and mobility aids are not yet law. This briefing clearly distinguishes between changes and improvements already being pursued and future legislative proposals. Do not treat proposed protections as current passenger rights. This resource does not constitute individual legal advice.
Primary sources
Early Inflammatory Arthritis: Why Timely Diagnosis and Treatment Matter
Source: National Early Inflammatory Autoimmune Diseases Audit (NEIAA), State of the Nation Report 2026. Published October 2026.
The National Early Inflammatory Autoimmune Diseases Audit (NEIAA) 2026 reported important associations between earlier treatment and improved outcomes for people with inflammatory arthritis. The audit included 10,695 patients across England, Wales and Jersey.
Key findings from the audit include:
- Patients starting DMARD treatment at their first specialist appointment had 48% higher odds of achieving remission at three months.
- Modelling suggested that up to 534 additional patients might have achieved early remission with earlier treatment.
- There was substantial variation between providers in treatment within the six-week NICE quality-standard target.
- Dedicated early inflammatory arthritis referral pathways were associated with faster assessment and treatment.
These are findings and recommendations from the national audit. They do not represent a new NICE treatment recommendation. Earlier treatment does not guarantee remission.
What this means for patients: DMARDs (disease-modifying antirheumatic drugs) are medicines used to slow the progression of inflammatory arthritis and reduce joint damage. Remission means a significant reduction or absence of active disease symptoms. If you have persistent joint swelling, pain or stiffness, discuss this with an appropriate healthcare professional. Suspected inflammatory arthritis may require specialist rheumatology assessment.
Medical information notice: This resource is for information only. It does not diagnose a condition, recommend individual treatment, or advise you to start, stop or change any prescribed medication. Always seek advice from your GP, rheumatology team or other qualified healthcare professional.
Our Resource Library is continually growing. We are committed to providing trusted information, practical guidance and community resources to help people live beyond arthritis.